Loading…

A melanoma multiepitope polypeptide induces specific CD8+ T-cell response

Strategies using epitope-based vaccination are being considered for melanoma immunotherapy, in an attempt to overcome failure of other modalities. In the present study, we designed and produced a multiepitope polypeptide for melanoma (MEP-mel), which contains three repeats of four antigenic epitopes...

Full description

Saved in:
Bibliographic Details
Published in:Cellular immunology 2007-11, Vol.250 (1), p.24-30
Main Authors: Levy, Adva, Pitcovski, Jacob, Frankenburg, Shoshana, Elias, Orit, Altuvia, Yael, Margalit, Hanna, Peretz, Tamar, Golenser, Jacob, Lotem, Michal
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Strategies using epitope-based vaccination are being considered for melanoma immunotherapy, in an attempt to overcome failure of other modalities. In the present study, we designed and produced a multiepitope polypeptide for melanoma (MEP-mel), which contains three repeats of four antigenic epitopes (gp100: 209–217 (210M); gp100: 280–288 (288V); Mart1: 26–35 (27L); tyrosinase: 368–376 (370D). The peptides were attached to each other by linkers containing sequences recognized by the proteasome, to improve protein cleavage and antigen presentation. The results show that peptide-specific T cells produced IFN-γ when stimulated with MEP-mel-transfected dendritic cells. The presentation of peptides by MEP-mel-transfected dendritic cells was proteasome-dependent and was more long-lasting than the presentation of exogenously delivered native peptides. When dendritic cells were loaded with MEP-mel protein, weak cross presentation was induced. The production of multiepitope molecules based on several peptides linked by sequences sensitive to proteasomal cleavage represents a promising new tool for the improvement of cancer immunotherapy.
ISSN:0008-8749
1090-2163
DOI:10.1016/j.cellimm.2008.01.001